Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CORT125281, 40mg, fasted, CORT125281, fasted
CORT125281 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAD Part 1 Placebo Cohort 1 Period 1 | PLACEBO_COMPARATOR | - |
| SAD Part 1 Active Cohort Period 1 | EXPERIMENTAL | - |
| SAD Part 1 Placebo Cohort 1 Period 2 | PLACEBO_COMPARATOR | - |
| SAD Part 1 Active Cohort 1 Period 2 | EXPERIMENTAL | - |
| SAD Part 1 Placebo Cohort 1 Period 3 | PLACEBO_COMPARATOR | - |
| SAD Part 1 Active Cohort 1 Period 3 | EXPERIMENTAL | - |
| SAD Part 2 Placebo Cohort 2 Period 4 | PLACEBO_COMPARATOR | - |
| SAD Part 2 Active Cohort 2 Period 4 | EXPERIMENTAL | - |
| SAD Part 2 Placebo Cohort 2 Period 5 | PLACEBO_COMPARATOR | - |
| SAD Part 2 Active Cohort 2 Period 5 | EXPERIMENTAL | - |
| SAD Part 2 Placebo Cohort 2 Period 6 | PLACEBO_COMPARATOR | - |
| SAD Part 2 Active Cohort 2 Period 6 | EXPERIMENTAL | - |
| MAD Placebo Cohort 1 | PLACEBO_COMPARATOR | - |
| MAD Active Cohort 1 | EXPERIMENTAL | - |
| MAD Placebo Cohort 2 | PLACEBO_COMPARATOR | - |
| MAD Active Cohort 2 | EXPERIMENTAL | - |
| MAD Placebo Cohort 3 | PLACEBO_COMPARATOR | - |
| MAD Active Cohort 3 | EXPERIMENTAL | - |
| MAD Placebo Cohort 4 | PLACEBO_COMPARATOR | - |
| MAD Active Cohort 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CORT125281, 40mg, fasted | DRUG | CORT125281 is supplied as capsules for oral dosing |
| Prednisone 25mg, fasted | DRUG | Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered |
| Placebo oral capsule, fasted | DRUG | Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered |
| Pioglitazone 15mg Tablet | DRUG | Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered |
| Placebo oral capsule, fed | DRUG | Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered |
| Prednisone 25mg, fed | DRUG | Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered |
| CORT125281, 120mg, fasted | DRUG | CORT125281 is supplied as capsules for oral dosing |
| CORT125281, 360mg, fasted | DRUG | CORT125281 is supplied as capsules for oral dosing |
| CORT125281, 720mg, fasted | DRUG | CORT125281 is supplied as capsules for oral dosing |
| CORT125281, 360mg, fed | DRUG | CORT125281 is supplied as capsules for oral dosing |
| CORT125281, 360mg | DRUG | CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal |
| CORT125281, 120mg | DRUG | CORT125281 is supplied as capsules for oral dosing once daily |
| CORT125281, 180mg | DRUG | CORT125281 is supplied as capsules for oral dosing twice daily |
| CORT125281, 240mg | DRUG | CORT125281 is supplied as capsules for oral dosing twice daily |
| Placebo oral capsule | DRUG | Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal |
Inclusion Criteria: 1. Give written informed consent 2. If male, have undergone vasectomy, with no wish to have the procedure reversed 3. If female, using appropriate precautions to avoid pregnancy, defined as of nonchildbearing potential (ie, postmenopausal or permanently sterilised) or using high...
CORT125281 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating single and multiple ascending doses. The drug is being developed by Corcept Therapeutics Incorporated.
CORT125281 is a small molecule developed by Corcept Therapeutics. The specific molecular target has not been disclosed in available clinical trial information. The drug is being studied in healthy volunteers to assess its safety, tolerability, and pharmacokinetics.
CORT125281 is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy volunteers.
CORT125281 is in Phase 1 clinical development. A Phase 1 trial studying single ascending doses (SAD) and multiple ascending doses (MAD) has been completed. The drug is investigational and has not been approved by regulatory authorities.
CORT125281 has one completed Phase 1 clinical trial, identified as NCT03335956, titled "CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)." The trial enrolled 48 healthy volunteers in the United Kingdom and was randomized, double-blind, and placebo-controlled.